Work

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Year: 2009

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v114.22.3905.3905

Authors: Srdan Verstovsek, Olatoyosi Odenike, Bart Scott, Zeev Estrov, Jorge Cortes, Deborah A. Thomas, Jeanette Wood, Kantharaj Ethirajulu, Ann Lowe, Huan J. Zhu, Hagop Kantarjian, H. Joachim Deeg

Institutions: The University of Texas MD Anderson Cancer Center, University of Chicago, Fred Hutch Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2566841041

FWCI: 6.509

Cites:

Cited by: 79

Related to: 10